Marker Therapeutics (NASDAQ:MRKR) Shares Down 6.9% – Should You Sell?

Marker Therapeutics, Inc. (NASDAQ:MRKR)’s stock price fell 6.9% during trading on Wednesday . The stock traded as low as $1.10 and last traded at $1.1450. Approximately 103,065 shares were traded during mid-day trading, an increase of 122% from the average session volume of 46,424 shares. The stock had previously closed at $1.23.

Analysts Set New Price Targets

MRKR has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Marker Therapeutics in a report on Wednesday, June 24th. HC Wainwright reissued a “buy” rating on shares of Marker Therapeutics in a report on Wednesday, May 20th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Marker Therapeutics currently has an average rating of “Hold” and a consensus price target of $10.00.

Marker Therapeutics Stock Down 6.9%

The business’s fifty day moving average is $1.37 and its two-hundred day moving average is $1.46. The firm has a market cap of $19.09 million, a price-to-earnings ratio of -1.88 and a beta of 1.50.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The firm had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.78 million. Marker Therapeutics had a negative return on equity of 73.29% and a negative net margin of 343.03%. Research analysts forecast that Marker Therapeutics, Inc. will post -1.17 EPS for the current year.

Institutional Trading of Marker Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRKR. Jane Street Group LLC acquired a new position in Marker Therapeutics during the 2nd quarter valued at about $33,000. Virtu Financial LLC bought a new stake in shares of Marker Therapeutics during the third quarter worth approximately $25,000. Two Sigma Investments LP acquired a new position in Marker Therapeutics in the third quarter valued at approximately $33,000. Boyer Financial Services Inc. bought a new position in Marker Therapeutics in the fourth quarter valued at approximately $57,000. Finally, XTX Topco Ltd grew its holdings in Marker Therapeutics by 166.6% during the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after acquiring an additional 36,269 shares during the period. 22.39% of the stock is currently owned by institutional investors and hedge funds.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.